Pfizer and OPKO Health get approval for NGENLA in Europe

European Commission has approved NGENLA, a long-acting growth hormone developed by Pfizer and OPKO Health. The drug is designed to treat short stature caused by growth hormone deficiency without closed epiphyses. NGENLA reduces the frequency of treatment from daily injections to one shot per week.